Antengene Corporation Limited
6996.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.16B
Close$
Share Statistics
| Market cap | $2.16 Billion |
|---|---|
| Enterprise Value | $1.65 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.38 |
| Beta | 0.37 |
| Outstanding Shares | 628,664,639 |
Return
| Return on Equity | -19.51% |
|---|---|
| Return on Assets | -11.72% |
| Return on Invested Capital | -9.85% |
Valuation & Multiples
| P/E Ratio | 33.95 |
|---|---|
| PEG | -8.95 |
| Price to Sales | 2.97 |
| Price to Book Ratio | 2.97 |
| Enterprise Value to Revenue | 2.57 |
| Enterprise Value to EBIT | -12.85 |
| Enterprise Value to Net Income | -10 |
| Total Debt to Enterprise | 0.16 |
| Debt to Equity | 0.28 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 21, 2026
EPS Estimate
$0.43
Average shareholder expectationRevenue Estimate
$516.36 M
Average shareholder expectationNext Earnings Call
Expected Date
March 19, 2027
EPS Estimate
$0.22
Average shareholder expectationRevenue Estimate
$372.04 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Antengene Corporation Limited
122 employees
CEO: Jay Mei Antengene Corporation Limited, a biopharmaceutical firm, is dedicated to developing advanced oncology treatments primarily within the Chinese market. Its active clinical development pipeline includes several innovative compounds. Among t...